Edition:
United States

GlaxoSmithKline PLC (GSK)

GSK on New York Consolidated

35.14USD
22 Nov 2017
Change (% chg)

$0.33 (+0.95%)
Prev Close
$34.81
Open
$35.20
Day's High
$35.22
Day's Low
$35.13
Volume
905,178
Avg. Vol
4,054,749
52-wk High
$44.53
52-wk Low
$34.72

Chart for

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 0.98
Market Cap(Mil.): $84,810.47
Shares Outstanding(Mil.): 2,459.34
Dividend: 0.50
Yield (%): 5.94

Financials

  Industry Sector
P/E (TTM): -- 31.69 15.46
EPS (TTM): -- -- --
ROI: -- 15.18 11.85
ROE: -- 16.59 15.83

U.S. FDA approves first two-drug HIV regimen in win for GSK

The U.S. Food and Drug Administration has approved the first two-drug regimen to treat HIV, the virus that causes AIDS, aimed at lessening the side effect burden of current treatments that combine three or four medicines.

3:52am EST

UPDATE 2-U.S. FDA approves first two-drug HIV regimen in win for GSK

* Two-drug approach differentiates GSK from Gilead (Adds context on GSK drive to improve pharma sales)

3:46am EST

U.S. FDA approves first two-drug HIV regimen

NEW YORK, Nov 21 The U.S. Food and Drug Administration on Tuesday approved the first two-drug regimen to treat HIV, the virus that causes AIDS, aimed at easing the side effects for long-term patients who are on the standard treatment involving three or more drugs.

Nov 21 2017

BRIEF-‍GlaxoSmithKline reports 13.3 percent stake in Spero Therapeutics

* ‍GlaxoSmithKline PLC reports a 13.3 percent stake in Spero Therapeutics Inc as of November 6 - SEC filing​ Source text: (http://bit.ly/2infUEI) Further company coverage:

Nov 16 2017

Europe approves GlaxoSmithKline's new triple lung drug

LONDON Europe has approved GlaxoSmithKline's new three-in-one inhaler for chronic lung disease, which the group hopes will help it keep its lead in respiratory medicine despite falling sales of older drug Advair.

Nov 16 2017

Europe approves GlaxoSmithKline's new triple lung drug

LONDON, Nov 16 Europe has approved GlaxoSmithKline's new three-in-one inhaler for chronic lung disease, which the group hopes will help it keep its lead in respiratory medicine despite falling sales of older drug Advair.

Nov 16 2017

BRIEF-GlaxoSmithKline says European Commission grants marketing authorisation for Trelegy Ellipta

* TRELEGY ELLIPTA ONCE-DAILY SINGLE INHALER TRIPLE THERAPY GAINS MARKETING AUTHORISATION IN EUROPE FOR TREATMENT OF COPD​ Source text for Eikon: Further company coverage:

Nov 16 2017

BRIEF-Glaxosmithkline posts Q1 consol profit

* Q1 CONSOL NET PROFIT EGP 18.2 ‍​MILLION VERSUS LOSS OF EGP 72.9 ‍​MILLION YEAR AGO

Nov 14 2017

BRIEF-GlaxoSmithkline receives European marketing authorisation for self-injectable formulation of Benlysta for treatment of systemic lupus erythematosus

* RECEIVES EUROPEAN MARKETING AUTHORISATION FOR SELF-INJECTABLE FORMULATION OF BENLYSTA FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS​

Nov 13 2017

AstraZeneca rides China wave as rival GlaxoSmithKline struggles

LONDON AstraZeneca is enjoying booming drug sales in China, helped by reforms to the country's regulatory system and an increased sales force, in sharp contrast to its British rival GlaxoSmithKline .

Nov 09 2017

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥6,155 -24.00
Procter & Gamble Co (PG.N) $88.15 -0.57
Johnson & Johnson (JNJ.N) $137.52 -0.82
Pfizer Inc. (PFE.N) $35.43 -0.11
Novartis AG (NOVN.S) CHF83.60 +0.05
Unilever NV (UNc.AS) €48.38 -0.32
Unilever NV (UNIA.AS) €48.41 -0.29
Unilever NV (UN_pa.AS) €989.00 --
Unilever NV (UN_p.AS) €303.50 --
Unilever NV (UN_pb.AS) -- --

Earnings vs. Estimates